雅各臣科研制药(02633.HK)拟斥资约1.13亿港元收购品牌中药业务公司43%股权
格隆汇7月22日丨雅各臣科研制药(02633.HK)发布公告,2019年7月22日,公司间接全资附属SampanDevelopmentLimited作为买方与该等卖方订立买卖协议,据此,买方同意按总代价约1.13亿港元收购目标公司OrizenCapitalLimited的43%股权。
OrizenCapitalLimited为于英属处女群岛注册成立的公司,为投资控股公司。于公告日期,目标集团主要从事品牌中药业务。
公告表示,就增强其品牌药业务组合而言,收购事项乃集团加速实施该方面战略的绝佳机遇,并为创造领先的品牌中药业务奠定基础,促进该业务为集团带来销售额、现金流及收益强劲增长。被收购业务与集团业务互为补充,预期会产生显着的协同效应,从而促进集团品牌中药业务的增长。此举巩固了集团的发展策略,即收购于战略上高度符合其长远业务发展及可为股东创造可观价值的业务或资产。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.